Harbour BioMed Announces Results of Phase Ib Clinical Trial of Porustobart in Combination with Toripalimab in Advanced High-Grade Neuroendocrine Neoplasms at AACR Annual Meeting

Porustobart in combination with toripalimab showed promising anti-tumor activity in advanced high-grade neuroendocrine neoplasms (NENs) The ORR and DCR we...

Harbour BioMed Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or...

Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis

Cambridge, MA, Rotterdam, NL, Suzhou, CN – March 6, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

CAMBRIDGE, Mass., February 14, 2023   Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Onc...

Harbour BioMed Announces IND Clearance for Novel G Protein-coupled Receptor HBM1022 Targeting CCR8 in the U.S.

HBM1022 is a monoclonal antibody generated from Harbour BioMed’s integrated G protein-coupled receptor (GPCR) platform HBM1022 presented cynomolgus ...

HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

Cambridge, MA, January 26, 2023   HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142...

Harbour BioMed Announces IND Clearance for HBM1007 Targeting CD73 in the U.S.

HBM1007 is a fully-human monoclonal antibody targeting CD73 HBM1007 is generated from Harbour Mice®  H2L2 platform With unique epitopes to...

Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 (HHLA2) Antibody by the U.S. FDA

HBM1020 is the globally first-in-class fully human monoclonal antibody targeting B7H7. HBM1020 is also the globally first-ever monoclonal antibody targeti...

Harbour BioMed Reports the Latest Progress from Phase I Clinical Trial of Porustobart in Combination with Toripalimab in Advanced Melanoma

Cambridge, MA, Rotterdam, NL, Suzhou, CN— December 8, 2022   Harbour BioMed (the “Company”, HKEX: 02142), today announced the pro...

Invitation | Harbour BioMed Investor Day 2022